Morningstar

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting CALQUENCE plus venetoclax ...
Cure Today

Calquence Remains Effective and Safe After 3 Years Compared With Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia

Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These ...
Business Wire

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with venetoclax demonstrated a statistically ...
Nasdaq

Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s CALQUENCE® (acalabrutinib) in ...
WebMD

Treating Chronic Lymphocytic Leukemia With Calquence

Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...
Cure Today

Calquence Combo May Improve Outcomes in Chronic Lymphocytic Leukemia

Calquence plus Venclexta, with or without Gazyva, significantly improved progression-free and overall survival in untreated CLL patients compared to chemoimmunotherapy. The study showed a higher ...
WebMD

Calquence Plus Venclexta: FDA Approves First All‑Oral Fixed‑Duration Regimen for Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...
FiercePharma

ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...
Healthline

Calquence Overview: Side Effects, Uses, Dosage, and More

Calquence (acalabrutinib) is a prescription drug approved to treat certain blood cancers, such as chronic lymphocytic leukemia. Calquence comes as an oral tablet. Calquence contains the active ...
Nasdaq

AstraZeneca Elated On Calquence Data, IMGN's IMGN632 Appears To Be Promising In AML, XRTX On Watch

(RTTNews) - Today's Daily Dose brings you news about AstraZeneca's new long-term data related to cancer drug Calquence; superior efficacy of Novartis' Scemblix compared to Bosulif in chronic myeloid ...
Business Wire

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

CLL is the most common type of leukemia in adults. 3 An estimated 18,500 people were treated for CLL in the 1st-line setting in the US in 2024. 4 Jennifer Brown, MD, PhD, Director of the CLL Center of ...